demonstrated in oral and lung squamous cell carcinoma that small molecule inhibition of C-X-C Motif Chemokine Receptor 2 (CXCR2), important to neutrophil chemotaxis, with SX-682 hindered tumor growth in the setting of PD-axis immune checkpoint inhibition and adoptive T cell transfer therapy (33). Here, CXCR2 is linked to squamous cell lung carcinoma.